Mariana Ingold

Dr. Mariana Ingold

Institut Pasteur de Montevideo, Montevideo, Uruguay

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2022 in Molecules
Verified
Journal Article
Open access
PDF file
MIMariana Ingold
Mariana Ingold
VSVictoria de la Sovera
Victoria de la Sovera
RDRosina Dapueto
Rosina Dapueto
PHPaola Hernández
Paola Hernández
WPWilliams Porcal
Williams Porcal
GLGloria López
Gloria López
Prostate and bladder cancers are commonly diagnosed malignancies in men. Several nitric oxide donor compounds with strong antitumor activity have been reported. Thus, continuing with our efforts to explore the chemical space around bioactive furoxan moiety, multicomponent reactions were employed for the rapid generation of molecular diversity and complexity. We herein report the use of Ugi and Groebke–Blackburn–Bienaymé multicomponent reactions under efficient, safe, and environmentally friendly conditions to synthesize a small collection of nitric-oxide-releasing molecules. The in vitro antiproliferative activity of the synthesized compounds was measured against two different human cancer cell lines, LNCaP (prostate) and T24 (bladder). Almost all compounds displayed antiproliferative activity against both cancer cell lines, providing lead compounds with nanomolar GI50 values against the cancer bladder cell line with selectivity indices higher than 10.

12 January 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
MVMaría Varela
María Varela
MLMiriam López
Miriam López
MIMariana Ingold
Mariana Ingold
DADiego Alem
Diego Alem
VPValentina Perini
Valentina Perini
PHPaola Hernández
Paola Hernández
Bladder cancer is a worldwide problem and improved therapies are urgently needed. In the search for newer strong antitumor compounds, herein, we present the study of three nitric oxide-releasing compounds and evaluate them as possible therapies for this malignancy. Bladder cancer cell lines T24 and 253J were used to evaluate the antiproliferative, antimigratory, and genotoxic effects of compounds. Moreover, we determined the NF-κB pathway inhibition, and finally, the survivin downregulation exerted by our molecules. The results revealed that compounds 1 and 3 exerted a high antiproliferative activity against bladder cancer cells through DNA damage and survivin downregulation. In addition, compound 3 reduced bladder cancer cell migration. We found that nitric oxide donors are promising molecules for the development of a new therapeutic targeting the underlying mechanisms of tumorigenesis and progression of bladder cancer.